Medcolcanna Organics Valuation

Is MCCN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MCCN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MCCN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MCCN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MCCN?

Key metric: As MCCN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MCCN. This is calculated by dividing MCCN's market cap by their current revenue.
What is MCCN's PS Ratio?
PS Ratio	2.7x
Sales	CA$316.61k
Market Cap	CA$848.69k

MCCN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	14.8x
Enterprise Value/EBITDA	-1.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MCCN's PS Ratio compare to its peers?

The above table shows the PS ratio for MCCN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.8x
NHP.H Lumiera Health	2x	n/a	CA$849.8k
GNOM Gnomestar Craft	6.6x	n/a	CA$854.1k
SUGR.H SugarBud Craft Growers	0.3x	n/a	CA$718.6k
OVAT Ovation Science	10.4x	n/a	CA$1.1m
MCCN Medcolcanna Organics	2.7x	n/a	CA$848.7k

Price-To-Sales vs Peers: MCCN is expensive based on its Price-To-Sales Ratio (2.7x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does MCCN's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

25 Companies	Price / Sales	Estimated Growth	Market Cap
AYR.A Ayr Wellness	0.2x	2.6%	US$78.92m
TIUM.U Cansortium	0.2x	n/a	US$22.65m
ACRG.A.U Acreage Holdings	0.09x	n/a	US$20.20m
MRV Nuvo Pharmaceuticals	0.2x	n/a	US$11.21m

25 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: MCCN is expensive based on its Price-To-Sales Ratio (2.7x) compared to the Canadian Pharmaceuticals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is MCCN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MCCN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MCCN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fennec Pharmaceuticals

US$127.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.59

8.0%

-43.4%

Verano Holdings

CA$829.5m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.14

-15.4%

-63.8%

Medexus Pharmaceuticals

CA$53.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.13

4.9%

38.3%